Tirzepatide Research Peptide — Dual GIP/GLP-1 Agonist
Tirzepatide is a synthetic peptide functioning as a dual agonist of both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is among the most studied metabolic peptides in current pharmaceutical research and has been the subject of extensive clinical investigation. For research purposes, it offers a well-characterized dual-pathway model for studying integrated incretin signaling.
Mechanism of Action
Tirzepatide’s dual agonist mechanism engages both the GIP and GLP-1 receptor pathways, which play distinct but complementary roles in glucose regulation and energy homeostasis. GLP-1 receptor activation influences appetite signaling and insulin secretion, while GIP receptor activation modulates nutrient-dependent insulin response and lipid metabolism. The combination of both mechanisms in a single molecule makes it a valuable compound for researchers studying incretin physiology.
Research Overview
Tirzepatide has been extensively studied in clinical trials examining its effects on glucose control and body weight in metabolic disease models. Its well-documented pharmacological profile makes it one of the most comprehensively characterized dual-agonist peptides available for research use.
Product Details
Format: Lyophilized powder | Purity: >99% | Testing: Third-party HPLC and MS verified | Packaging: Sterile sealed vial | Multiple dosages available | Pricing from $29.99 per vial
Storage Instructions
Store lyophilized powder in a cool, dry place. Refrigerate after reconstitution at 2–8°C. Protect from light.
Tirzepatide is intended for research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.
